Industry Reports

April 2023 Global Innovative Drug Report

30 June 2023
2 min read

This April 2023 Global Innovative Drug Report, based on data from the PatSnap Synapse database, offers a comprehensive overview of the latest advancements in the pharmaceutical industry. Divided into four parts, it examines the R&D status, active patents, mechanisms of action, clinical trials, competitive landscape, and other pertinent factors of each selected drug.

Download the report to gain valuable insights into:

1.The first approved drugs in April 

2.Comprehensive analysis of newly introduced medications

3.Global drugs under Expedited Review Pathway in April 

4.In-depth analysis of selected ERP drugs 

Global Innovative Drug Report Overview 

1.) First Approved Drugs in April 

In April 2023, a total of 8 drugs received global approval, encompassing a diverse range of therapeutic categories. These notable approvals consisted of 2 Prophylactic vaccines, 2 Small molecule drugs (SMDs), 1 Monoclonal antibody (mAb), 1 Hematopoietic stem cell treatment, 1 Oligonucleotide antisense therapy, and 1 Live biotherapeutic product.

April 2023 Global Approved Drugs,Synapse

2.) Comprehensive analysis of newly introduced medications

This report highlights 5 recently approved drugs for an in-depth analysis. Let’s take a closer look at the report content for Vilobelimab, which includes the following comprehensive details:

Vilobelimad Snapshot & R&D Status, PatSnap Synapse
Vilobelimad Active Patent & Analysis, PatSnap Synapse
Vilobelimad Analysis Continued, PatSnap Synapse

3.) Global drugs under Expedited Review Pathway in April 

In April 2023, 45 drugs underwent Expedited Review pathways (ERP). This cohort includeds a diverse range of designations, with 16 drugs holding the esteemed Orphan Drug designation, 12 designated as Fast Track, 6 deemed Breakthrough Therapy, 4 granted Priority Review, 2 bestowed with the Rare Pediatric Disease designation, 2 under the Innovative Licensing and Access Pathway (ILAP), 1 marked for Accelerated Approval, 1 authorized for Emergency Use, and 1 falling under the PRIME (EU) program.

April 2023 Global Drugs Subject to Expedited Review, Synapse 

4.) In-depth analysis of selected ERP drugs 

For this report, we selected 6 ERP drugs to analyze. Let’s delve into the report content for Sibeprenlimab, which presents the following in-depth details:

Sibeprenlimab Snapshot & R&D Status, PatSnap Synapse
Sibeprenlimab Active Patents & Analysis, PatSnap Synapse
Sibeprenlimab Analysis Continued, PatSnap Synapse

Gain Access to the Comprehensive Report for FREE – Download Now! If you aren’t registered for Synapse (registration is required to download the report), click here to register for free.

Copyright Statement: This report is the sole property of PatSnap and is protected under copyright laws. Any reproduction, excerpting, or other use of this report without explicit authorization from PatSnap is strictly prohibited. Authorized products must be used within the scope of authorization and must include a clear indication of the source. PatSnap reserves the right to investigate any violations of this statement and pursue legal action as necessary. For inquiries regarding authorization, please contact phs@patsnap.com.

Get the full information on benegrastim
Drug Insights
4 min read
Get the full information on benegrastim
29 June 2023
Benegrastim is a fusion protein targeting CSF-3R (GCSFR). It is used for the treatment of neutropenia, fever, breast cancer, Parkinson's disease, and other conditions.
Read →
Overview of the Development Progress of PARP-7 Drug Target
Overview of the Development Progress of PARP-7 Drug Target
28 June 2023
PARP7 functions by catalyzing the transfer of a single ADP-ribose unit onto substrates, altering their functionality.
Read →
mRNA Vaccines: Embracing Change and Moving Forward
Advanced Tech.
5 min read
mRNA Vaccines: Embracing Change and Moving Forward
28 June 2023
mRNA vaccines involve delivering mRNA encoding antigen proteins into the human body, which is then translated directly into antigens, inducing an immune response.
Read →
March 2023 Global Innovative Drug Report
March 2023 Global Innovative Drug Report
28 June 2023
The report offers a comprehensive overview of the latest advancements in the pharmaceutical industry.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.